

Figure S1. Workflow for predicting the structure of aptamers and selecting target proteins.

Table S1. Plasma membrane proteins differentially expressed in the MDA-MB-231 strain selected after the validation stage.

Gene	ID UNIPROT	Cellular location (Uniprot)
CSKP	O14936-3	plasma membrane
TMEM205	K7ELQ9	plasma membrane
TM209	Q96SK2-2	plasma membrane
TM245	Q9H330-2	plasma membrane
SCAM4	Q969E2-2	plasma membrane
AGRE5	P48960	plasma membrane

G3V2K7	G3V2K7	plasma membrane
TM9S3	Q9HD45	plasma membrane
AT2B1	P20020-6	plasma membrane
AT2B3	Q16720-8	plasma membrane
E9PL82	E9PL82	plasma membrane
1A03HLA-A	P04439	plasma membrane
TSP1	P07996	plasma membrane
CD151	P48509	plasma membrane
VAMP7	P51809	plasma membrane
ADAM9	Q13443	plasma membrane
E41L2	O43491	plasma membrane
E9PPD9	E9PPD9	plasma membrane
TMX4	A2BDY9	plasma membrane
CD63	F8VV56	plasma membrane
HLA-A	P10316	plasma membrane
EGFR	P00533	plasma membrane
PIP4P2	D6RBT7	plasma membrane
TMCC1	O94876	plasma membrane
TM55B	U6CTL2	plasma membrane
CD44	P16070-4	plasma membrane
EPHA2	P29317	plasma membrane
NCS1	P62166	plasma membrane
TMEM106C	Q9NUM4	plasma membrane
CEMIP2	Q9UHN6	plasma membrane
MAGI3	Q5TCQ9	plasma membrane
TMEM237	Q96Q45	plasma membrane
TMEM181	Q9P2C4	plasma membrane
VAPA	Q9P0L0	plasma membrane
TMED10	G3V2K7	plasma membrane
TMCO4	Q5TGY1	plasma membrane
CD46	Q6VE48	plasma membrane
SMAP1	Q8IYB5	plasma membrane
TMEM199	Q8N511	plasma membrane
TMTG3	Q6ZXV5	plasma membrane




Figure S2. Representation of the electrostatic potential of the proteins selected for the molecular docking step. Analysis of the electrostatic potential of the CASPK (A), TM9S3 (B), TMEM205 (C), and CD151 (D) proteins. Blue indicates a positive charge and red indicates a negative charge.